Jun Matsubayashi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Jun Matsubayashi has a total of 161 co-authors. Here are the top co-authors by number of shared publications:
- Norihiko Ikeda
Department of Surgery Tokyo Medical University Tokyo Japan
18 shared publications - Yoshihisa Shimada
Department of Thoracic Surgery, Tokyo Medical University, Tokyo, Japan
18 shared publications - Genichiro Ishii
Department of Pathology and Clinical Laboratories National Cancer Center Hospital East Kashiwa Japan
13 shared publications - Hideki Furuya
Clinical Research Support Office, National Cancer Center Hospital East, Kashiwa, Japan
13 shared publications - Hiroyoshi Nishikawa
Division of Cancer Immunology, National Cancer Center Research Institute, Tokyo, Japan
13 shared publications - Joji Samejima
Department of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Japan
13 shared publications
Latest Publications
- Open Access
- 6 April 2026
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 16 (4) , 205
Personalized Prediction of Postoperative Recurrence in Lung Squamous Cell Carcinoma: Integrating AI-Based Nuclear Morphometry and Clinical Data
Background: This study employed artificial intelligence (AI) to analyze quantitative nuclear morphological features obtained from digital pathology images to predict postoperative recurrence in patients with lung squamous cell carcinoma (LSQCC). We aimed to develop a prediction model that contributes to the realization of ‘personalized postoperative management’ tailored to individual tumor biology by integrating AI-extracted morphological features with clinical information. Methods: A total of 185 of the 253 surgically resected LSQCC cases were included; 136 were randomly assigned to the training set and 49 to the test set. Nuclear features from manually selected regions of interest were extracted and used to build AI-based prediction models. Three recurrence models were developed: recurrence within 2 years, within 5 years, and a three-category model (≤2 years, 3–5 years, >5 years or no recurrence). Support vector machine (SVM) and random forest (RF) algorithms were applied to each, yielding six predictive models. An ensemble approach was used to calculate AI-based risk scores, and a “total risk score” was developed by integrating these with the pathologic stage. Results: All six AI models demonstrated stable predictive performance, with AUC values ranging from 0.76 to 0.91. Kaplan–Meier analysis showed that the total risk score provided the most precise risk stratification (p < 0.005), with clearer separation between risk groups than the AI-based risk score alone. Conclusions: The integration of AI-based nuclear morphology analysis and clinical data provides an objective and practical tool for personalized postoperative management in LSQCC. This approach enables tailored clinical decision-making by identifying patients at high risk for early recurrence and customizing postoperative treatment plans to meet the specific needs of each individual.
- 6 April 2026
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 16 (4) , 205
Open AccessPersonalized Prediction of Postoperative Recurrence in Lung Squamous Cell Carcinoma: Integrating AI-Based Nuclear Morphometry and Clinical Data
Background: This study employed artificial intelligence (AI) to analyze quantitative nuclear morphological features obtained from digital pathology images to predict postoperative recurrence in patients with lung squamous cell carcinoma (LSQCC). We aimed to develop a prediction model that contributes to the realization of ‘personalized postoperative management’ tailored to individual tumor biology by integrating AI-extracted morphological features with clinical information. Methods: A total of 185 of the 253 surgically resected LSQCC cases were included; 136 were randomly assigned to the training set and 49 to the test set. Nuclear features from manually selected regions of interest were extracted and used to build AI-based prediction models. Three recurrence models were developed: recurrence within 2 years, within 5 years, and a three-category model (≤2 years, 3–5 years, >5 years or no recurrence). Support vector machine (SVM) and random forest (RF) algorithms were applied to each, yielding six predictive models. An ensemble approach was used to calculate AI-based risk scores, and a “total risk score” was developed by integrating these with the pathologic stage. Results: All six AI models demonstrated stable predictive performance, with AUC values ranging from 0.76 to 0.91. Kaplan–Meier analysis showed that the total risk score provided the most precise risk stratification (p < 0.005), with clearer separation between risk groups than the AI-based risk score alone. Conclusions: The integration of AI-based nuclear morphology analysis and clinical data provides an objective and practical tool for personalized postoperative management in LSQCC. This approach enables tailored clinical decision-making by identifying patients at high risk for early recurrence and customizing postoperative treatment plans to meet the specific needs of each individual.
- Open Access
Prediction of Lymphovascular Invasion in Early–Stage Lung Adenocarcinoma Using Artificial Intelligence–Based Radiomics
Objectives: This study utilized artificial intelligence (AI)–based radiomics analysis of computed tomography (CT) images using a modified U–Net for lung nodule segmentation and convolutional neural network based on VGG–16 to predict lymphovascular invasion (LVI) in stage 0–I lung adenocarcinoma. Additionally, the study investigated whether combining radiomics data with serum microRNA (miR)–30d level as a potential biomarker could enhance predictive performance. Methods: A total of 1265 patients who underwent complete resection between 2008 and 2018 were included. AI–based CT analysis was performed, and logistic regression was applied to predict LVI using 35 imaging features. A risk score (RS) generated from 840 patients in the derivation cohort was used to identify a high–risk group, with validation performed using 425 patients. Additionally, 47 cases with extracellular vesicle (EV)–derived miR–30d level data were analyzed to evaluate the value of the integrated approach. Results: Among all the patients, 467 patients (36.9%) were LVI–positive, and LVI was independently associated with poorer overall survival. The receiver operating characteristic curve for LVI based on the RS yielded an area under the curve of 0.899. For LVI prediction, the sensitivity, specificity, and accuracy were 84.8%, 83.7%, and 83.9%, respectively, in the derivation group, and 82.3%, 79.4%, and 80.5%, respectively, in the validation group. The integrated approach with miR–30d enhanced the predictability of LVI, achieving a sensitivity of 93.3%, specificity of 70.5%, and accuracy of 85.1%. Conclusions: AI–based radiomics demonstrated high effectiveness for predicting LVI, with RSs showing broad clinical applications. The addition of EV–derived miR–30d modestly improved predictability.
Open AccessPrediction of Lymphovascular Invasion in Early–Stage Lung Adenocarcinoma Using Artificial Intelligence–Based Radiomics
Objectives: This study utilized artificial intelligence (AI)–based radiomics analysis of computed tomography (CT) images using a modified U–Net for lung nodule segmentation and convolutional neural network based on VGG–16 to predict lymphovascular invasion (LVI) in stage 0–I lung adenocarcinoma. Additionally, the study investigated whether combining radiomics data with serum microRNA (miR)–30d level as a potential biomarker could enhance predictive performance. Methods: A total of 1265 patients who underwent complete resection between 2008 and 2018 were included. AI–based CT analysis was performed, and logistic regression was applied to predict LVI using 35 imaging features. A risk score (RS) generated from 840 patients in the derivation cohort was used to identify a high–risk group, with validation performed using 425 patients. Additionally, 47 cases with extracellular vesicle (EV)–derived miR–30d level data were analyzed to evaluate the value of the integrated approach. Results: Among all the patients, 467 patients (36.9%) were LVI–positive, and LVI was independently associated with poorer overall survival. The receiver operating characteristic curve for LVI based on the RS yielded an area under the curve of 0.899. For LVI prediction, the sensitivity, specificity, and accuracy were 84.8%, 83.7%, and 83.9%, respectively, in the derivation group, and 82.3%, 79.4%, and 80.5%, respectively, in the validation group. The integrated approach with miR–30d enhanced the predictability of LVI, achieving a sensitivity of 93.3%, specificity of 70.5%, and accuracy of 85.1%. Conclusions: AI–based radiomics demonstrated high effectiveness for predicting LVI, with RSs showing broad clinical applications. The addition of EV–derived miR–30d modestly improved predictability.
- 24 December 2024
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 51 (3) , 109565
Immunotherapy-extended survival in patients with recurrent pulmonary pleomorphic carcinoma following surgery
- 24 December 2024
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 51 (3) , 109565
Immunotherapy-extended survival in patients with recurrent pulmonary pleomorphic carcinoma following surgery
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1–Positive NSCLC: A Phase II Trial (EAST ENERGY)
Supplementary Table S2: Representativeness of Study Participants.
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1–Positive NSCLC: A Phase II Trial (EAST ENERGY)
Supplementary Table S2: Representativeness of Study Participants.
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1–Positive NSCLC: A Phase II Trial (EAST ENERGY)
Supplementary Table S5: Surgical methods and approaches in patients who underwent surgery.
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1–Positive NSCLC: A Phase II Trial (EAST ENERGY)
Supplementary Table S5: Surgical methods and approaches in patients who underwent surgery.
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Appendix S1 from Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1–Positive NSCLC: A Phase II Trial (EAST ENERGY)
Supplementary Appendix S1: EAST_ENERGY_Protocol_v7.
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Appendix S1 from Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1–Positive NSCLC: A Phase II Trial (EAST ENERGY)
Supplementary Appendix S1: EAST_ENERGY_Protocol_v7.
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S6 from Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1–Positive NSCLC: A Phase II Trial (EAST ENERGY)
Supplementary Table S6: Interval from preoperative treatment to surgery and cases of postponed surgery.
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S6 from Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1–Positive NSCLC: A Phase II Trial (EAST ENERGY)
Supplementary Table S6: Interval from preoperative treatment to surgery and cases of postponed surgery.
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1–Positive NSCLC: A Phase II Trial (EAST ENERGY)
Supplementary Figure S3: Spatial analysis of the immunosuppressive cells neighboring the effector cells.
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1–Positive NSCLC: A Phase II Trial (EAST ENERGY)
Supplementary Figure S3: Spatial analysis of the immunosuppressive cells neighboring the effector cells.
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Appendix S2 from Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1–Positive NSCLC: A Phase II Trial (EAST ENERGY)
Supplementary Appendix S2: EAST_ENERGY_Protocol_amendment.
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Appendix S2 from Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1–Positive NSCLC: A Phase II Trial (EAST ENERGY)
Supplementary Appendix S2: EAST_ENERGY_Protocol_amendment.
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Data from Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1–Positive NSCLC: A Phase II Trial (EAST ENERGY)
Purpose:Angiogenesis inhibitors are known to modify tumor immunity. Combination of angiogenesis inhibitors with immune checkpoint inhibitors has shown efficacy against many types of cancers, including non–small cell lung cancer (NSCLC). We investigated the feasibility of neoadjuvant therapy with pembrolizumab and ramucirumab, a VEGFR-2 antagonist for patients with PD-L1–positive NSCLC, and its influence on the tumor microenvironment.Patients and Methods:Patients with pathologically proven, PD-L1–positive, clinical stage IB to IIIA NSCLC were eligible. Patients received two cycles of pembrolizumab (200 mg/body) and ramucirumab (10 mg/kg) every 3 weeks. Surgery was scheduled 4 to 8 weeks after the last dose. The primary endpoint was the major pathologic response rate by a blinded independent pathologic review. The sample size was 24 patients. Exploratory endpoints were evaluated to elucidate the effects of neoadjuvant therapy on the tumor microenvironment.Results:The 24 eligible patients were enrolled between July 2019 and April 2022. The major pathologic response rate was 50.0% (90% confidence interval, 31.9%–68.1%). Six patients showed pathologic complete response. Grade 3 adverse events (AE) occurred in nine patients (37.5%), including three immune-related AEs (acute tubulointerstitial nephritis in two cases and polymyalgia rheumatica in one case). There were no grade 4 or 5 AEs. The transcriptome and multiplex IHC results suggested that tumors with greater CD8+ T-cell infiltration and higher expression of effector molecules at the baseline could show better sensitivity to treatment.Conclusions:This new neoadjuvant combination of pembrolizumab plus ramucirumab was feasible, and anti-VEGF agents may enhance the effects of immune checkpoint inhibitors.
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Efficacy, Safety, and Influence on the Tumor Microenvironment of Neoadjuvant Pembrolizumab plus Ramucirumab for PD-L1–Positive NSCLC: A Phase II Trial (EAST ENERGY)
Purpose:Angiogenesis inhibitors are known to modify tumor immunity. Combination of angiogenesis inhibitors with immune checkpoint inhibitors has shown efficacy against many types of cancers, including non–small cell lung cancer (NSCLC). We investigated the feasibility of neoadjuvant therapy with pembrolizumab and ramucirumab, a VEGFR-2 antagonist for patients with PD-L1–positive NSCLC, and its influence on the tumor microenvironment.Patients and Methods:Patients with pathologically proven, PD-L1–positive, clinical stage IB to IIIA NSCLC were eligible. Patients received two cycles of pembrolizumab (200 mg/body) and ramucirumab (10 mg/kg) every 3 weeks. Surgery was scheduled 4 to 8 weeks after the last dose. The primary endpoint was the major pathologic response rate by a blinded independent pathologic review. The sample size was 24 patients. Exploratory endpoints were evaluated to elucidate the effects of neoadjuvant therapy on the tumor microenvironment.Results:The 24 eligible patients were enrolled between July 2019 and April 2022. The major pathologic response rate was 50.0% (90% confidence interval, 31.9%–68.1%). Six patients showed pathologic complete response. Grade 3 adverse events (AE) occurred in nine patients (37.5%), including three immune-related AEs (acute tubulointerstitial nephritis in two cases and polymyalgia rheumatica in one case). There were no grade 4 or 5 AEs. The transcriptome and multiplex IHC results suggested that tumors with greater CD8+ T-cell infiltration and higher expression of effector molecules at the baseline could show better sensitivity to treatment.Conclusions:This new neoadjuvant combination of pembrolizumab plus ramucirumab was feasible, and anti-VEGF agents may enhance the effects of immune checkpoint inhibitors.